Anti-KRAS G12D mTCR PBL is under clinical development by Gilead Sciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Anti-KRAS G12D mTCR PBL’s likelihood of approval (LoA) and phase transition for Metastatic Colorectal Cancer took place on 30 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 30 May 2022 increased Anti-KRAS G12D mTCR PBL’s LoA and PTSR for Non-Small Cell Lung Cancer, increased LoA and PTSR for Ovarian Cancer, increased LoA and PTSR for Pancreatic Cancer, and increased LoA and PTSR for Prostate Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Anti-KRAS G12D mTCR PBL Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Anti-KRAS G12D mTCR PBL overview

Gene therapy is under development for the treatment of metastatic colorectal cancer, pancreatic cancer, non-small cell lung cancer, ovarian cancer, prostate cancer. The therapeutic candidate constitutes T cells genetically engineered to express T cell receptor (TCR) specific for G12D KRAS.

Gilead Sciences overview

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

Quick View Anti-KRAS G12D mTCR PBL LOA Data

Report Segments
  • Innovator
Drug Name
  • Anti-KRAS G12D mTCR PBL
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Gilead Sciences
  • Originator: U.S. National Institutes of Health
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.